PMID- 29704192
OWN - NLM
STAT- MEDLINE
DCOM- 20190219
LR  - 20190320
IS  - 1573-7322 (Electronic)
IS  - 1382-4147 (Linking)
VI  - 23
IP  - 3
DP  - 2018 May
TI  - SGLT2 inhibition and heart failure-current concepts.
PG  - 409-418
LID - 10.1007/s10741-018-9703-2 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a major risk factor for several cardiovascular 
      (CV) conditions, including heart failure (HF). However, until recently, no 
      therapy to treat patients with diabetes could also reduce CV risks related to HF. 
      The EMPA-REG OUTCOME trial with empagliflozin was the first to demonstrate 
      significant cardioprotective benefits in this population. Its impressive 35% 
      reduction in hospitalizations for HF drew the attention of the scientific 
      community to the possibility that pharmacologic sodium-glucose cotransporter 2 
      (SGLT2) inhibition could be part of the armamentarium for treating patients with 
      HF, with and without diabetes. The recently published CANVAS Program (with 
      canagliflozin) and real-life data from the CVD-Real Study (using dapagliflozin, 
      empagliflozin, and canagliflozin) further strengthened this hypothesis, 
      suggesting that the observed benefit is not restricted to a particular drug, but 
      is rather a class effect. This review explores the effects of pharmacologic SGLT2 
      inhibitors' use in cardiac function and discusses the potential role of this 
      class of medication as a treatment for HF.
FAU - Custodio, Joaquim Silva Jr
AU  - Custodio JS Jr
AD  - Department of Health Family, Medical School of Bahia, Federal University of 
      Bahia, Praca XV de Novembro, s/n degrees  - Largo do Terreiro de Jesus, Salvador, BA, 
      40026-010, Brazil. jocsjunior@uol.com.br.
AD  - Post-graduate Program in Interactive Processes of Organs and Systems, Health & 
      Science Institute, Federal University of Bahia, Salvador, BA, Brazil. 
      jocsjunior@uol.com.br.
FAU - Duraes, Andre Rodrigues
AU  - Duraes AR
AD  - Department of Health Family, Medical School of Bahia, Federal University of 
      Bahia, Praca XV de Novembro, s/n degrees  - Largo do Terreiro de Jesus, Salvador, BA, 
      40026-010, Brazil.
AD  - Roberto Santos General Hospital - SESAB, Salvador, BA, Brazil.
FAU - Abreu, Marconi
AU  - Abreu M
AD  - Department of Internal Medicine, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Albuquerque Rocha, Natalia
AU  - Albuquerque Rocha N
AD  - Department of Internal Medicine, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Roever, Leonardo
AU  - Roever L
AD  - Department of Clinical Research, Federal University of Uberlandia, Uberlandia, 
      MG, Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Heart Fail Rev
JT  - Heart failure reviews
JID - 9612481
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism
MH  - Heart Failure/etiology/*metabolism
MH  - Humans
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2/drug effects/*metabolism
MH  - Sodium-Glucose Transporter 2 Inhibitors/*pharmacology
OTO - NOTNLM
OT  - Cardiovascular outcomes
OT  - Diabetes mellitus
OT  - Heart failure
OT  - SGLT2 inhibitors
EDAT- 2018/04/29 06:00
MHDA- 2019/03/21 06:00
CRDT- 2018/04/29 06:00
PHST- 2018/04/29 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
PHST- 2018/04/29 06:00 [entrez]
AID - 10.1007/s10741-018-9703-2 [pii]
AID - 10.1007/s10741-018-9703-2 [doi]
PST - ppublish
SO  - Heart Fail Rev. 2018 May;23(3):409-418. doi: 10.1007/s10741-018-9703-2.